GLUE: monterosatx.com Net earnings per share for the last 12 months

Symbol and logo of brand Monte Rosa Therapeutics, Inc. (GLUE)

Monte Rosa Therapeutics (GLUE) is developing an asset-light model by outsourcing drug production to third-party contractors. The 12-month rolling EPS on the precise GURU.Markets chart demonstrates profit dynamics, where -1.54 serves as the final level marker. The absence of revenue leaves the company dependent on investments, while the success of protein degradation innovations supported by Roche determines the viability of the base.

GLUE (Monte Rosa Therapeutics) Net earnings per share (EPS TTM) history from 07/04/2022 to 11/10/2026

Analytical breakdowns for Monte Rosa Therapeutics

- share price and expert price forecast:
Stock Quotes Monte Rosa Therapeutics|GLUE - Fair Value Consensus
- market capitalization information:
Market Valuation Monte Rosa Therapeutics, Inc.|GLUE - Aggregate Business Value
- balance sheet net asset value indicators:
Book Value per Share Monte Rosa Therapeutics|GLUE - Book Capitalization|Market Value to Book Value Ratio monterosatx.com|GLUE - Aggregate Asset Value
- business debt structure and liquidity details:
Total Debt to Capital Monte Rosa Therapeutics|GLUE - Long-Term Indebtedness to Equity|Short-Term Debt to Capital Monte Rosa Tx|GLUE - Company Cumulative Debt|Debt to Book Value Monte Rosa Therapeutics, Inc.|GLUE - Amount of Long-Term Liabilities|Company Short-Term Debts Monte Rosa Therapeutics|Quick Ratio monterosatx.com
- net income and valuation multiples indicators:
GLUE - Company Profit|Future Profit Monte Rosa Therapeutics|GLUE - Company Value to Net Income|Projected Price to Earnings Monte Rosa Therapeutics, Inc.|GLUE - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Monte Rosa Therapeutics, Inc.|GLUE - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Monte Rosa Therapeutics|GLUE - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months monterosatx.com|GLUE - Earnings per share increase in current year|Earnings growth forecast for next year Monte Rosa Therapeutics
Basic company analysis:Monte Rosa Therapeutics - GLUE
Manufactured products of Monte Rosa Therapeutics Inc

The stability of Monte Rosa Therapeutics (GLUE) relies on partnerships with pharmaceutical behemoths, yet the actual business value depends on the success of clinical trials for molecular glues. The trailing 12-month net income per share trend reflects the final profit distributed across the total share issuance, allowing investors to separate speculative noise from the company's actual ability to generate capital over the long term.

Who Monte Rosa Therapeutics competes with

GMAB: Net earnings per share for the last 12 months|Earnings per share for the trailing year EXEL (exelixis.com)|NUVL (Nuvalent) - Net earnings per share for the last 12 months|KYMR: Earnings per share for the last four quarters|IDYA (IDEAYA Bio) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Enliven Corp|Earnings per share for the last twelve months ORIC Pharmaceuticals (ORIC)|RLAY (relaytx.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) NRIX (Nurix Therapeutics, Inc.)|Net earnings per share for the trailing year Tyra Biosciences Inc|Verastem Inc - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Cullinan Corp|IMRX (Immuneering Corporation) - Net earnings per share for the last 12 months|CCCC: Earnings per share for the last four quarters|BDTX (Black Diamond Therapeutics) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Repare Therapeutics, Inc. RPTX|Net earnings per share (EPS TTM) PMVP|karyopharm.com - Earnings per share for the last 12 months|Propanc Biopharma - Net earnings per share for the last 12 months|Earnings per share for the trailing year BGMS|AADI: Net earnings per share for the last 12 months|Aileron Therapeutics - Earnings per share for the last four quarters|BPMC: Net earnings per share (EPS TTM)|GlycoMimetics - Earnings per share for the trailing year|SWTX (SpringWorks Therapeutics) - Net earnings per share (EPS TTM)